![](data:image/svg+xml;charset=utf-8,<svg height="32" width="135" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
₹ 3,966.00
Open
3974.6High
3975Low
3949.25Prev Close
3964.05P/E
76.09Median P/E
47.6P/B
8.24Median P/B
3.88Market Cap
1,052.85BPEG
1.69Div.Yield
0.76Bid
3,959.30Ask
3,966.00Large Cap
1,052.85B Mkt. Cap.Volatility
-Beta
0.57Genie Says
Influencer Count
-| Days | BSE | NSE |
|---|
| 5 | 3,842.12 | 3,842.93 |
| 10 | 3,792.60 | 3,792.31 |
| 20 | 3,703.77 | 3,704.29 |
| 50 | 3,626.95 | 3,627.59 |
| 100 | 3,695.86 | 3,696.48 |
| 300 | 3,675.69 | 3,676.20 |
BSE
532488NSE
DIVISLABISIN
INE361B01024Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. In addition to generic business, the Company, through its custom synthesis business, supports pharma companies for their patented products business right from gram scale requirements for clinical trials to launch, as well as late life cycle management. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
Kiran Divi
Chief Executive Officer, Whole-time DirectorL. Kishore Babu
Chief Financial OfficerM. Satish Choudhury
Compliance Officer, Company SecretaryMurali Divi
Managing Director, Executive DirectorNilima Divi
Whole-Time Director - (Commercial)Nimmagadda Ramana
Executive DirectorS. Devendra Rao
Whole-time Director (Manufacturing)